Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects (Q83392390)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

1 reference

C Beglinger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

B Poller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

E Arbit

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

C Ganzoni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

S Gass

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

I Gomez-Orellana

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

J Drewe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

1 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

468-474

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

The gut hormone peptide YY regulates appetite

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Inhibition of food intake in obese subjects by peptide YY3-36

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Gut hormone PYY(3-36) physiologically inhibits food intake

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Effect of peptide YY3-36 on food intake in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Glucagon-like peptide-1: a potent regulator of food intake in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Effects of peripheral administration of PYY3-36 on feed intake and plasma acyl-ghrelin levels in pigs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Glucagon-like peptide 1(GLP-1) in biology and pathology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Half-disappearance time of endogenous GLP-1 immunoreactivity in man

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Peptide YY: a potential therapy for obesity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Oral absorption enhancement of cromolyn sodium through noncovalent complexation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Strategies for delivery of peptides utilizing absorption-enhancing agents

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Challenges for the oral delivery of macromolecules

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Strategies to improve oral drug bioavailability

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

The molecular weight dependence of nasal absorption: the effect of absorption enhancers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Approaches and opportunities in colon-specific drug delivery.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

The effect of intestinal bacteria adherence on drug diffusion through solid films under stationary conditions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: implications in peptide delivery to the colon

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Chitosan Capsules for Colon-Specific Drug Delivery: Improvement of Insulin Absorption from the Rat Colon

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Oral heparin: status review

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.35

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238651%20AND%20SRC:MED&resulttype=core&format=json